Pharmaceutical

Gilead jumps into a competitive Protein degradation field, signs a USD 45 M Nurix deal Gilead Sciences is turning to Nurix Therapeutics for enhancing cancer pipeline. Gilead is ready to pay USD 45 million upfront, and if all the targets are achieved the deal could reach up to USD 2.3 billion. Nurix is a drug developing company focused on operating the ubiquitin system, which breaks down damaged, unneeded and disease-causing proteins. The partnership will arm Nurix to use its technology to accelerate its drug discovery especially the ones that use E3 ligases—enzymes that regulate protein levels in human cells and degrade specific protein targets. On the other hand,...